Cargando…
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection
A majority of patients with metastatic colorectal cancer (mCRC) experience recurrence post curative-intent surgery. The addition of adjuvant chemotherapy has shown to provide limited survival benefits when applied to all patients. Therefore, a biomarker to assess molecular residual disease (MRD) acc...
Autores principales: | Lonardi, Sara, Nimeiri, Halla, Xu, Chang, Zollinger, Daniel R., Madison, Russell W., Fine, Alexander D., Gjoerup, Ole, Rasola, Cosimo, Angerilli, Valentina, Sharma, Shruti, Wu, Hsin-Ta, Palsuledesai, Charuta C., Malhotra, Meenakshi, Aleshin, Alexey, Loupakis, Fotios, Renkonen, Elise, Hegde, Priti, Fassan, Matteo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569771/ https://www.ncbi.nlm.nih.gov/pubmed/36232827 http://dx.doi.org/10.3390/ijms231911529 |
Ejemplares similares
-
mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022) -
Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches
por: Ceccon, Carlotta, et al.
Publicado: (2022) -
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013) -
The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018) -
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
por: Marmorino, Federica, et al.
Publicado: (2019)